Important development created in new COVID-19 vaccine created by the group of Prof Salanti
STOCKHOLM, Jan. 13, 2021 /PRNewswire/ — On Tuesday January 12th, in Mother nature Communications, robust preclinical benefits for a new COVID-19 vaccine, produced by the group of Prof. Salanti from College of Copenhagen, ExpreS2ion Biotech, its joint enterprise companion AdaptVac and the Stop-nCoV consortium, was revealed. Dependent on these final results, a medical demo application (CTA) for a medical Period I/II review for the COVID-19 vaccine has been submitted.
About the preclinical results
Readouts from the information display that ABNCoV2 has the likely to be the ideal-in-course COVID-19 vaccine with a more than 100-fold bigger amount of neutralizing antibodies in contrast with released preclinical animal information from currently accredited COVID-19 vaccines, this kind of as Pfizer-BioNTech’s, Moderna’s, and AstraZeneca-Oxford’s vaccines. The full paper is out there on line and can be go through listed here.
About the CTA
The Medical demo software (CTA) for the ABNCoV2 capsid virus-like particle (cVLP) centered COVID-19 vaccine was submitted to the Central Committee on Investigation Involving Human Subjects (CCMO) in the Netherlands very last week. It is expected to be permitted under a COVID-19 rapid-observe overview progress. This can be observed as another considerable milestone following the November 2020 announcement of the successful GMP production of the vaccine. ExpreS2ion expects to present preliminary scientific Phase I/IIa results right before conclusion of Q1 2021.
Because March 2020, Attana has been assisting the staff of Prof. Ali Salanti at the University of Copenhagen in the improvement of this COVID-19 vaccine with two of Attana’s QCM Biosensors blended with exploration intelligence. As can be observed in the paper released, Attana’s know-how has foremost been utilized to examine kinetic interactions in between RBD antigens and CLP-RBD to hACE2. Also, Attana and ExpreS2ion not too long ago recognized a strategic partnership such as a offer arrangement of proteins. In addition, Attana technologies has been utilised to good quality regulate the vaccine for the IND submission.
Attana CEO Teodor Aastrup responses:
“I’m thrilled for our companions sake and for the future of vaccine progress and desire to congratulate all events associated for attaining these remarkable success. I am now wanting ahead to investigate this collaboration even more and to with any luck , work much more intently with each Prof. Salanti and the crew at ExpreS2ion in the in the vicinity of time long run.”
For far more facts, make sure you get in touch with:
+46 () 8 674 57 00
The Board of directors for Attana contemplate that the information in this press release is not probably to have a considerable result on the share selling price but is of common curiosity for the shareholders and that’s why should be communicated.
Attana was launched in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Considering that then, Attana has made proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in-vitro diagnostics (IVD) instrument. Attana products and solutions and investigate expert services are made use of by Big Pharma, biotech organizations and educational institutions in the daily life sciences. To find out extra about our most up-to-date providers and products, you should visit www.attana.se or make contact with product [email protected]
This information was brought to you by Cision http://information.cision.com
The next files are offered for down load: